​

Cullinan Therapeutics (CGEM) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CGEM Stock Forecast

Cullinan Therapeutics (CGEM) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $34.75, with a high of $40.00 and a low of $27.00. This represents a 141.82% increase from the last price of $14.37.

$5 $12 $19 $26 $33 $40 High: $40 Avg: $34.75 Low: $27 Last Closed Price: $14.37

CGEM Stock Rating

Cullinan Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

CGEM Price Target Upside V Benchmarks

TypeNameUpside
StockCullinan Therapeutics141.82%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1414
Avg Price Target$35.00$35.25$32.64
Last Closing Price$14.37$14.37$14.37
Upside/Downside143.56%145.30%127.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26111---12
Sep, 26110---11
Aug, 26111---12
Jul, 26111---12
Jun, 26111---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 25, 2026H.C. Wainwright$35.00$15.44126.68%143.56%
Sep 14, 2026BTIG$40.00$20.7392.96%178.36%
Aug 17, 2026David DaiUBS$27.00$20.7630.06%87.89%
Jul 29, 2026BTIG$39.00$17.47123.24%171.40%
May 08, 2026Wedbush$37.00$14.76150.68%157.48%
Apr 28, 2026Robert BurnsH.C. Wainwright$30.00$12.79134.56%108.77%
Mar 11, 2026Wedbush$36.00$14.31151.57%150.52%
Mar 10, 2026Alex ThompsonStifel Nicolaus$28.00$15.1185.31%94.85%
Feb 02, 2026Guggenheim$30.00$11.96150.84%108.77%
Jan 08, 2026H.C. Wainwright$27.00$10.77150.70%87.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 25, 2026H.C. WainwrightBuyBuyhold
Sep 14, 2026BTIGBuyBuyhold
Sep 14, 2026Cowen & Co.BuyBuyhold
Aug 17, 2026UBSBuyBuyhold
Jul 29, 2026BTIGBuyBuyhold
Jun 10, 2026William BlairOutperformOutperformhold
May 08, 2026WedbushOutperformOutperformhold
Apr 28, 2026H.C. WainwrightBuyBuyhold
Feb 17, 2026CitigroupBuyinitialise
Feb 02, 2026GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.48$-3.69$-3.11----
Avg Forecast$-1.28$-4.09$-3.04$-3.10$-3.00$-2.33$-2.87
High Forecast$-0.89$-4.05$-2.95$-2.51$-2.42$-0.05$-1.60
Low Forecast$-1.67$-4.13$-3.33$-4.09$-4.65$-4.12$-4.14
Surprise %15.63%-9.78%2.30%----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.94M------
Avg Forecast$18.91M-$1.67M$10.65M$33.02M$56.13M$58.02M
High Forecast$23.38M-$2.24M$14.28M$33.16M$56.64M$77.82M
Low Forecast$14.46M-$1.10M$7.02M$32.89M$55.62M$38.24M
Surprise %0.15%------

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.57M$-153.16M$-167.38M$-219.88M---
Avg Forecast$-53.08M$-169.76M$-130.49M$-137.20M$-146.98M$-86.74M$-119.11M
High Forecast$-36.82M$-168.11M$-122.60M$-104.43M$-100.70M$-2.28M$-66.31M
Low Forecast$-69.35M$-171.42M$-138.38M$-169.96M$-193.27M$-171.21M$-171.96M
Surprise %23.53%-9.78%28.28%60.27%---

CGEM Forecast FAQ

Is Cullinan Therapeutics stock a buy?

Cullinan Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cullinan Therapeutics is a favorable investment for most analysts.

What is Cullinan Therapeutics's price target?

Cullinan Therapeutics's price target, set by 8 Wall Street analysts, averages $34.75 over the next 12 months. The price target range spans from $27 at the low end to $40 at the high end, suggesting a potential 141.82% change from the previous closing price of $14.37.

How does Cullinan Therapeutics stock forecast compare to its benchmarks?

Cullinan Therapeutics's stock forecast shows a 141.82% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cullinan Therapeutics over the past three months?

  • October 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cullinan Therapeutics’s EPS forecast?

Cullinan Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-2.33 in 2027, and $-2.87 in 2028.

What is Cullinan Therapeutics’s revenue forecast?

Cullinan Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $33.02M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $56.13M, and $58.02M for 2028.

What is Cullinan Therapeutics’s net income forecast?

Cullinan Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-147M, representing a -33.15% decrease from the reported $-220M in 2025. Projections indicate $-86.744M in 2027, and $-119M in 2028.